Clinical Trials
2 trialsNCT02581930 2026-04-30
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03021460 2026-01-20
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Mayo Clinic
Phase 1 Active not recruiting